Novartis Institute for Tropical Diseases (NITD)
Fighting neglected infectious diseases
The Novartis Institute for Tropical Diseases (NITD) is dedicated to finding new medicines to treat neglected, infectious diseases. As a small-molecule drug discovery research institute, it combines the drug-discovery expertise and cutting-edge technologies of Novartis to fight infectious tropical diseases, including Dengue fever, Tuberculosis and Malaria among others.
In developing countries where these diseases are endemic, Novartis will make treatments readily available and without profit to poor patients. NITD was set up as a public-private partnership between Novartis and the Singapore Economic Development Board (EDB) in 2002. Since then, it has grown to more than 100 researchers and supporting staff. As a major center of excellence for drug discovery, NITD will offer exceptional teaching and training opportunities for post-doctoral fellows and graduate students.
NITD is organized into four units:
The Disease Biology unit is responsible for generating new projects for the tropical neglected diseases pipeline and supports the other functional units, and includes experts in tropical diseases, structural biology, and bioinformatics.
The Drug Discovery unit provides all key biological data to support medicinal chemistry efforts from high-throughput screening assay development to drug candidate selection, and includes experts in enzymology, high-throughput screening (HTS) assay development, pharmacology and high-throughput biology.
The Chemistry team has the task of turning leads identified from screening into drug candidates from synthesis of new structurally related molecules to optimization, and includes medicinal chemists together with computational chemists.
The DMPK / Pharmacology unit coordinates in-house and outside efforts to study drug candidates, using in vitro profiling assays and in vivo studies to ensure acceptable pharmacokinetics properties of the selected molecules.
NITD is dependent on the early formation of global collaborations. We work with organizations on early research activities, such as target identification and high-throughput screening, and later stages of drug development and patient outreach. NITD is constantly seeking collaboration opportunities. For more details, contact us by e-mail: firstname.lastname@example.org
T Cell Monitoring of Chemotherapy in Experimental Rat Tuberculosis.
Foo, DG (Foo, Damian Guang)1; Tay, HC (Tay, Hui Chien)1; Siew, JY (Siew, Jie Yee)1; Singhal, A (Singhal, Amit)1; Camacho, L (Camacho, Luis)1; Bifani, P (Bifani, Pablo)1; Dartois, V (Dartois, Veronique)1; Herve, M (Herve, Maxime)1, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(8): 3677-3683 Aug 2011
Reagent Precoated Targets for Rapid In-Tissue Derivatization of the Anti-Tuberculosis Drug Isoniazid Followed by MALDI Imaging Mass Spectrometry.
Manier, ML (Manier, M. Lisa)1; Reyzer, ML (Reyzer, Michelle L.)1; Goh, A (Goh, Anne)2; Dartois, V (Dartois, Veronique)2; Via, LE (Via, Laura E.)3; Barry, CE (Barry, Clifton E., III)3; Caprioli, RM (Caprioli, Richard M.)1,4,5,6, JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 22(8): 1409-1419 Aug 2011
Anti-infectives: Can cellular screening deliver?
Keller, TH (Keller, Thomas H.)2; Shi, PY (Shi, Pei-Yong)1; Wang, QY (Wang, Qing-Yin)1, CURRENT OPINION IN CHEMICAL BIOLOGY, 15(4): 529-533 Aug 2011
Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B.
Yeung, BKS (Yeung, Bryan K. S.), CURRENT OPINION IN CHEMICAL BIOLOGY, 15(4): 523-528 Aug 2011
Characterization of early host responses in adults with dengue disease.
Tolfvenstam, T (Tolfvenstam, Thomas)1,2; Lindblom, A (Lindblom, Anna)1; Schreiber, MJ (Schreiber, Mark J.)3; Ling, L (Ling, Ling)1; Chow, A (Chow, Angelia)4; Ooi, EE (Ooi, Eng Eong)4; Hibberd, ML (Hibberd, Martin L.)1, BMC INFECTIOUS DISEASES, 11, 209 Aug 2 2011
- NITD fact sheet